Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397428/
https://www.ncbi.nlm.nih.gov/pubmed/30886737
http://dx.doi.org/10.1136/rmdopen-2018-000692corr1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397428/
https://www.ncbi.nlm.nih.gov/pubmed/30886737
http://dx.doi.org/10.1136/rmdopen-2018-000692corr1

Ejemplares similares